Our experts spoke about the strategies to meet the quality & regulatory requirements of cell & gene therapies (CGT), and Lonza's New Product Introduction process (NPI) for CGT manufacturing – how to identify issues early on, reduce quality & compliance risks, and how to avoid delays and rework.

Speakers:

Andreas Wirth, Vice President, Global Head of Quality, Cell & Gene Technologies and Personalized Medicine

Christoph Meyer, Senior Director, Global Head of Quality Control, Cell & Gene Technologies

You may also be interested in:
Allogeneic
Autologous
Exosomes
iPSCs
Viral Vectors
Manufacturing: cGMP
Regulatory Services
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
Poster
3D Linkage Analysis with Digital PCR for rAAV Characterization Beyond Genomic Titer: Integrity and...
Abstract: Recombinant adeno-associated virus (rAAV) has emerged as the vector of choice for in vivo...
Dev on Demand - CGT - process development
Poster
Extracellular Vesicles: Engineering New Therapeutic Delivery Modalities
Abstract: Extracellular Vesicles (EVs), including exosomes, are emerging as promising natural...
Poster
Plasmid Engineering to Improve AAV Productivity and Packaging Efficiency
Abstract: The genome packaging efficiency (full to total capsid ratio, or F/T ratio) for...
Poster
Enabling Commercial AAV Manufacturing by Xcite® AAV Stable Producer Cell Lines
Abstract: The superior safety profile and transduction efficiency make AAV an excellent viral...
Poster
Overcoming Challenges to the Commercialization of Lentiviral-Based Therapies: A Scalable and Robust...
Abstract: Due to their ability to deliver larger cargo, transduce both dividing and non-dividing...
micro image
Technical/Service brief
GS Discovery® Transient Expression System
With GS Discovery® you can.... Speed up therapeutic candidate selection with...
Microdosing graphic
Webinar (on-demand)
Micro-dosing – Powder in Capsule Technology Pathway from Development to Commercialization
Micro-dosing can accelerate the journey of a drug product from early development through to...
Webinar (on-demand)
Solving Bispecific Antibody Heavy-Light Chain Mispairing with bYlok® Technology
Lonza’s bYlok® bispecific pairing technology is an innovative solution that drives correct...
AAV manufacturing
Webinar (on-demand)
Improving AAV Productivity and Packaging Efficiency for Transient and Producer Cell Lines Through...
Adeno-associated virus (AAV) gene therapy has shown immense promise in treating various genetic...
Video
How Does bYlok® Technology Work and How Can It Improve Bispecific Production?
Bispecific antibodies offer numerous potential clinical benefits, and the number of bispecifics in...
PBPK_scientist-in-lab-with-monitor
Webinar (on-demand)
PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development
When coupled with in vitro measurements, PBPK modeling is effective in early development for 1)...
White paper
The Early Advantage for IND Success and Beyond
Many of the decisions made during the early days of building and compiling the manufacturing...